Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition
FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company’s focus on growth opportunities in obesity and diabetes medications.
Related Articles
-
Boeing’s new defense-minded engineering center in Daytona promises 400 jobs -
Musk loses crown as world’s richest to software giant Larry Ellison in new Bloomberg ranking -
US health care hiring slowdown is warning for broader job market -
Study links more frequent and severe heat waves to pollution from major fossil fuel producers -
Are EVs really better for the environment? Study checks role of coal, battery and range
The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs.
The streamlining would save 8 billion Danish krone ($1.25 billion) by the end of 2026, savings that are to be redirected to diabetes and obesity, including research and development, the company said. Novo Nordisk also makes Ozempic, a diabetes drug that also can result in weight loss.